Spero Therapeutics (SPRO) Q3 2026 earnings summary

Executive summary

• FDA approval of Utebzi in June 2026 marked a strategic pivot from antibiotic development toward SP001, now the sole product candidate in clinical development; commercial value from Utebzi depends on GSK.

• SP001, licensed from Innovent in July, is a CD40L antibody being developed for IgG4-related disease; a Phase 2 trial is expected in Q2 2027, subject to FDA clearance of a U.S. IND.

Financial highlights

• Q3 2026 revenue was $0, versus $5.4M in Q3 2025; the prior-year quarter included $2.4M in grant revenue and $3.0M in GSK collaboration revenue.

• Q3 net loss was $44.3M versus $7.4M YoY; loss per share was $0.76 versus $0.13.

• 9M 2026 revenue was $0.3M versus $25.5M; net loss was $61.0M versus $22.9M, with $35.0M of SP001 acquired IPR&D expense.

• 9M R&D expense fell to $9.5M from $32.9M, while total operating expenses rose to $59.6M from $50.6M, primarily reflecting the one-time SP001 license payment.

Outlook and guidance

• Cash and cash equivalents of $107.9M at September 30 are expected to fund operating expenses and required capital spending into H2 2029 under the current operating plan.

• SP001 Phase 2 in IgG4-RD is expected in Q2 2027, subject to FDA clearance of the U.S. IND; the Innovent agreement requires an IND filing within 12 months of July 8, 2026, subject to specified extensions.

• Beyond the current runway, or if plans change, additional funding may be required; potential sources include equity or debt financing, collaborations and grants, with spending reductions possible if funding is unavailable.